When thinking about the future of pharma these days, we often find ourselves looking not at the big-name companies, but at the smaller firms at the cutting-edge of the industry. (It’s not just by chance that the industry has been dominated by M&A for the last couple of years.)
London, UK-based Rexgenero has secured with partners £1.4 million in funding for a £1.8 million project from the UK’s innovation agency Innovate UK, for an industrial research project on the commercial manufacture of its product REX-001.
Cost regulators for NHS-funded therapies in England and Wales have issued updated guidelines for the treatment of wet AMD, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis, but the GMC says doctors should not fear prescribing Roche's Avastin off-label if they believe it is clinically appropriate and in the patient's best interest.
The European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic therapy.
Digitally-augmented multi-channel engagement has proved to be a useful approach for working with patients. However, it is easy for developers to default to a patient-facing website or an app that looks good and sounds impressive, but in practice doesn’t supply what patients want and need
The model that sees information flow linearly, from pharmaceutical companies, to healthcare professionals, or patient groups and patients, is outmoded and doesn’t work well for any of the parties involved.